View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Moody's assigns A2 rating to Bristol-Myers Squibb's sr. notes; outlook...

Moody's Investors Service ("Moody's") assigned an A2 rating to the new senior unsecured notes issuance of Bristol-Myers Squibb Company ("Bristol"). There are no changes to Bristol's existing ratings including the A2 senior unsecured ratings and the outlook remains unchanged at negative. Proceeds o...

Bristol-Myers Squibb Company: Update to credit analysis after confirma...

Our credit view of this issuer reflects its large scale and solid free cash flow tempered by commercial and pipeline execution risk.

Moody's confirms Bristol-Myers Squibb at A2; outlook is negative

Moody's Investors Service ("Moody's") confirmed the ratings of Bristol-Myers Squibb Company ("Bristol"). The ratings confirmed include the A2 ratings on senior unsecured bonds and a senior unsecured revolving credit facility, the (P)A2 senior unsecured shelf rating, the (P)A3 subordinated shelf rati...

Bristol-Myers Squibb Company: Update following ratings under review fo...

Our credit view of this issuer reflects its limited revenue diversity with three largest drugs driving over 60% of sales and its pipeline execution risk.

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 9, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: November 30, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Bristol Myers Squibb Co: 1 director

A director at Bristol Myers Squibb Co bought 8,500 shares at 49.810USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

Moody's assigns A2 ratings to Bristol's sr. notes; stable outlook

Moody's Investors Service ("Moody's") assigned an A2 ratings to the new senior unsecured notes offering of Bristol-Myers Squibb Company ("Bristol"). There are no changes to Bristol's existing ratings including the A2 senior unsecured long-term ratings or the Prime-1 short-term ratings. The outlook r...

Moody's: Bristol's acquisition of Mirati adds approved cancer drug and...

Moody's Investors Service commented that Bristol-Myers Squibb Company's (A2 stable) announcement that it will acquire Mirati Therapeutics, Inc. is credit negative. The deal enhances Bristol's oncology product portfolio and pipeline opportunities, but carries commercial and R&D execution risk given M...

Bristol-Myers Squibb Company: Acquisition of Mirati adds approved canc...

The deal offers long-term revenue opportunities in oncology but will moderately erode Bristol's credit metrics and it brings execution risk.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Bristol-Myers Squibb Company: Revlimid erosion steepens, but new produ...

Our credit view of this issuer reflects its solid global scale and modest financial leverage, tempered by very large exposure to upcoming patent cliffs.

Bristol-Myers Squibb Company: Key facts and statistics - LTM March 202...

A summary company profile, detailing Bristol-Myers Squibb Company’s business operations and financial highlights.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch